NEW YORK (GenomeWeb) – Fred Hutchinson Cancer Research Center spinout Adaptive Biotechnologies has acquired immune sequencing company Sequenta, the companies said today.

Adaptive Biotechnologies CEO Chad Robins will remain as CEO of the combined company. Tom Willis, Sequenta co-founder and CEO, and Malek Faham, co-founder and chief scientific officer of Sequenta, will join the senior leadership team and report to Robins. Willis and John Stuelpnagel, Sequenta's chairman, will join the board of directors.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.